drugset
Drugs / BAZLITORAN
last change Jun 2018 re-read 3 minutes ago

BAZLITORAN

also known as IMO 8400

Oligonucleotide (other) targets TLR7, TLR8, TLR9 via inhibition

Developed for
Waldenstrom macroglobulinemia · dermatomyositis · diffuse large B-cell lymphoma · psoriasis
Investigated by
Idera Pharmaceuticals, Inc.

Trials 5

today NCT02612857 · Ph 2 NCT02363439 · Ph 1/2 NCT02252146 · Ph 1/2 NCT02092909 · Ph 1/2 NCT01899729 · Ph 2
201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/23 trials
Phase 1/2 NCT02363439 Nov 2014 → Dec 2016 Waldenstrom macroglobulinemia Idera Pharmaceuticals, Inc. Completed No outcome recorded
Phase 1/2 NCT02252146 Jun 2014 → Dec 2016 diffuse large B-cell lymphoma Idera Pharmaceuticals, Inc. Completed No outcome recorded
Phase 1/2 NCT02092909 Mar 2014 → Apr 2017 Waldenstrom macroglobulinemia Idera Pharmaceuticals, Inc. Terminated No outcome recorded
Phase 22 trials
Phase 2 NCT02612857 Nov 2015 → May 2018 dermatomyositis Idera Pharmaceuticals, Inc. Completed No outcome recorded
Phase 2 NCT01899729 May 2013 → Apr 2014 psoriasis Idera Pharmaceuticals, Inc. Completed No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as BAZLITORAN ChEMBL registry synonym — accepted as the source's own label CHEMBL4297995 ↗
Known as IMO 8400 “IMO 8400 is a second-generation oligonucleotide antagonist of endosomal Toll-like receptors (TLR) 7, TLR8 and TLR9.” NCT01899729 ↗
5

NCT02252146 ↗

NCT01899729 ↗

NCT02363439 ↗

NCT02092909 ↗

NCT02612857 ↗
Action Inhibit “In vitro and in multiple animal models of autoimmune disease, IMO-8400 blocks immune activation mediated through TLR7, 8 and 9.” NCT01899729 ↗
1

“Toll-like receptor 7 antagonist” CHEMBL4297995 ↗
Modality Oligonucleotide (other) “IMO-8400 is a first-in-class, oligonucleotide-based antagonist of TLRs 7, 8, and 9.” PMID 27876460 ↗ Nov 2016
Route Subcutaneous “IMO-8400 0.075 mg/kg q wk x 12 wk by subcutaneous injection” NCT01899729 ↗
Target TLR7 “Toll-like receptor 7 antagonist” CHEMBL4297995 ↗
Target TLR8 “IMO 8400 is a second-generation oligonucleotide antagonist of endosomal Toll-like receptors (TLR) 7, TLR8 and TLR9.” NCT01899729 ↗
Target TLR9 “IMO 8400 is a second-generation oligonucleotide antagonist of endosomal Toll-like receptors (TLR) 7, TLR8 and TLR9.” NCT01899729 ↗